You are here

Article Text

Article menu
Download PDFPDF
Unexpected outcome (positive or negative) including adverse drug reactions
CASE REPORT
Detection of a new melanoma in a patient treated with fingolimod
  1. Yves Michiels1,
  2. Olivier Bugnon1,2,
  3. Jean-François Michiels3 and
  4. Sophie Mazellier3
  1. 1 Center for Primary Care and Public Health (Unisanté), University of Lausanne, Lausanne, Switzerland
  2. 2 Community Pharmacy Unit, Pharmaceutical Sciences section, Universities of Geneva and Lausanne, Geneva, Switzerland
  3. 3 Laboratoire Central d’Anatomie et Cytologie Pathologique, Centre Hospitalier Universitaire de Nice, Hôpital Pasteur, CHU Nice, Nice, France
  1. Correspondence to Dr Yves Michiels, yves.michiels{at}hospvd.ch

Abstract

In addition to the TRANSFORMS, FREEDOMS, INFORMS studies, very few publications have identified new cases of skin cancer in patients treated with fingolimod. Here, we present the case of a 52-year-old Caucasian patient with relapsing remitting multiple sclerosis for 19 years, with a phototype II with blue eyes, light brown hair, no personal or family history of melanoma and a low number of naevi (<10). She did not experience intense sun exposure in childhood as well as severe sunburn and did not practise sessions in ultraviolet cabins. This case is distinguished from other published cases, usually superficial spreading malignant melanoma by its unclassifiable histological character. The occurrence of skin cancers in patients with multiple sclerosis remains exceptional, but new cases have recently emerged requiring the strengthening of dermatological follow-up of such patients.

  • multiple sclerosis
  • dermatology
  • malignant disease and immunosuppression
  • neurology (drugs and medicines)

https://doi.org/10.1136/bcr-2018-227951

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Contributors YM and OB are involved in conduct, reporting, conception and design of the study. J-FM and SM are involved in data analysis.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; externally peer reviewed.

    • Patient consent for publication Obtained.